Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study-Reference-Cited by-同舟云学术

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Published:2014-09 Issue:10 Volume:15 Page:1090-1099
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Burger Jan A,Keating Michael J,Wierda William G,Hartmann Elena,Hoellenriegel Julia,Rosin Nathalie Y,de Weerdt Iris,Jeyakumar Ghayathri,Ferrajoli Alessandra,Cardenas-Turanzas Marylou,Lerner Susan,Jorgensen Jeffrey L,Nogueras-González Graciela M,Zacharian Gracy,Huang Xuelin,Kantarjian Hagop,Garg Naveen,Rosenwald Andreas,O'Brien Susan

Funder

Pharmacyclics Inc, Cancer Prevention and Research Institute of Texas, Leukemia & Lymphoma Society, the National Cancer Institute

MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies;Hallek;Blood,2013

2. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

3. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia;Furman;N Engl J Med,2014

4. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions;Goede;N Engl J Med,2014

5. Genomic aberrations and survival in chronic lymphocytic leukemia;Dohner;N Engl J Med,2000

Cited by 303 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08

2. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC);eClinicalMedicine;2024-07

3. Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion;Cellular Oncology;2024-04-25

4. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

5. Rituximab improves Clinical Outcomes of CAR-T therapy for r/r B-ALL via sensitizing Leukemia Cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion;2023-11-22